On October 1, 2021, Song Hai and Shen Li's research group collaborated to discover a new mechanism for the establishment of intratumoral heterogeneity and drug resistance in small cell lung cancer

Small cell lung cancer ( the Small C ELL Lung Cancer, of SCLC ) about the onset of lung cancer by 15% , while belonging to one neuroendocrine cancer, a high degree of malignancy, fast growth, early metastasis and extensive, five-year survival electrode Low, is one of the cancers with the highest mortality rate in humans .

2021 Nian 10 Yue 1 day my hospital Song Hai Task Force in cooperation with the research group in Shen Li Science Advances delivered a presentation entitled YAP drives fate conversion and chemoresistance of small cell lung cancer articles for small cell lung tumor heterogeneity And the mechanism of drug resistance has been deeply explored, which provides a new theoretical basis for the treatment of small cell lung cancer

In a variety of tumors, the expression of YAP/TAZ , a co-transcriptional activator of the Hippo pathway, is up-regulated or activated, thereby promoting the occurrence and development of tumors .

At the same time, the researchers also found that tumor cells activated by YAP were significantly resistant to the chemotherapy drugs Cisplatin and Etoposide .

Figure 1 : YAP regulates the heterogeneity and drug resistance of small cell lung cancer

In summary, this study revealed YAP / TAZ the activation and the NOTCH signaling pathway interactions in small cell lung tumor heterogeneity and resistance to establish regulation mechanisms

Institute of Life Science, Zhejiang University, Wu Qingzhe postdoctoral, doctoral and Liu Yu Ning Guo Jingxin is co-first author of the paper, Hai Song professor and professor Shen Li as co-corresponding author

Original link: https://